AU2002342533B2 - Prevention of addiction in pain management - Google Patents

Prevention of addiction in pain management Download PDF

Info

Publication number
AU2002342533B2
AU2002342533B2 AU2002342533A AU2002342533A AU2002342533B2 AU 2002342533 B2 AU2002342533 B2 AU 2002342533B2 AU 2002342533 A AU2002342533 A AU 2002342533A AU 2002342533 A AU2002342533 A AU 2002342533A AU 2002342533 B2 AU2002342533 B2 AU 2002342533B2
Authority
AU
Australia
Prior art keywords
analgesic
gvg
day
composition according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002342533A
Other languages
English (en)
Other versions
AU2002342533A1 (en
Inventor
Charles R. Ashby Jr.
Jonathan D. Brodie
Stephen L. Dewey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Brookhaven Science Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Associates LLC filed Critical Brookhaven Science Associates LLC
Publication of AU2002342533A1 publication Critical patent/AU2002342533A1/en
Application granted granted Critical
Publication of AU2002342533B2 publication Critical patent/AU2002342533B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002342533A 2001-05-14 2002-04-08 Prevention of addiction in pain management Ceased AU2002342533B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/853,548 US20020187996A1 (en) 2001-05-14 2001-05-14 Prevention of addiction in pain management
US09/853,548 2001-05-14
PCT/US2002/011072 WO2002091990A2 (en) 2001-05-14 2002-04-08 Prevention of addiction in pain management

Publications (2)

Publication Number Publication Date
AU2002342533A1 AU2002342533A1 (en) 2003-05-01
AU2002342533B2 true AU2002342533B2 (en) 2007-07-05

Family

ID=25316324

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002342533A Ceased AU2002342533B2 (en) 2001-05-14 2002-04-08 Prevention of addiction in pain management

Country Status (21)

Country Link
US (3) US20020187996A1 (enExample)
EP (1) EP1392301B1 (enExample)
JP (1) JP2004534029A (enExample)
KR (1) KR20040020054A (enExample)
CN (1) CN100528156C (enExample)
AT (1) ATE473001T1 (enExample)
AU (1) AU2002342533B2 (enExample)
BR (1) BR0209613A (enExample)
CA (1) CA2446639C (enExample)
CZ (1) CZ20033380A3 (enExample)
DE (1) DE60236927D1 (enExample)
ES (1) ES2348637T3 (enExample)
HR (1) HRP20030892A2 (enExample)
HU (1) HUP0402326A3 (enExample)
IL (1) IL158762A0 (enExample)
MX (1) MXPA03010407A (enExample)
NO (1) NO331509B1 (enExample)
NZ (1) NZ529614A (enExample)
PL (1) PL368505A1 (enExample)
WO (1) WO2002091990A2 (enExample)
YU (1) YU89003A (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080053423A (ko) * 2000-07-31 2008-06-12 니코메드 댄마크 에이에스 코 투여용 펜타닐 조성물
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105497896A (zh) * 2015-03-31 2016-04-20 苏州大学 一种肿瘤耐药的靶点及其应用
EP4230199A4 (en) 2020-12-04 2024-07-31 Laboratorios Silanes, S.A. de C.V. COATED AND STABLE SOLID PHARMACEUTICAL COMPOSITION OF AN ANALGESIC AND AN ANTIEPILEPTIC AGAINST PAIN
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007583A2 (en) * 1998-08-05 2000-02-17 Brookhaven Science Associates Treatment of addiction and addiction-related behavior

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007583A2 (en) * 1998-08-05 2000-02-17 Brookhaven Science Associates Treatment of addiction and addiction-related behavior

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caraceni A et al.(1999). J. Pain Symptom management,17(6):441-5 *

Also Published As

Publication number Publication date
US20030004176A1 (en) 2003-01-02
HRP20030892A2 (en) 2005-08-31
EP1392301A4 (en) 2004-07-14
MXPA03010407A (es) 2004-05-05
NZ529614A (en) 2006-08-31
CA2446639C (en) 2010-11-02
CN1531431A (zh) 2004-09-22
HUP0402326A3 (en) 2008-04-28
EP1392301B1 (en) 2010-07-07
JP2004534029A (ja) 2004-11-11
CA2446639A1 (en) 2002-11-21
ATE473001T1 (de) 2010-07-15
CZ20033380A3 (cs) 2005-03-16
US20020187996A1 (en) 2002-12-12
YU89003A (sh) 2006-08-17
EP1392301A2 (en) 2004-03-03
DE60236927D1 (de) 2010-08-19
ES2348637T3 (es) 2010-12-10
US20030134868A1 (en) 2003-07-17
WO2002091990A3 (en) 2003-03-27
CN100528156C (zh) 2009-08-19
BR0209613A (pt) 2004-12-07
HUP0402326A2 (hu) 2005-02-28
PL368505A1 (en) 2005-04-04
NO331509B1 (no) 2012-01-16
WO2002091990A2 (en) 2002-11-21
NO20035038D0 (no) 2003-11-13
US6939876B2 (en) 2005-09-06
IL158762A0 (en) 2004-05-12
KR20040020054A (ko) 2004-03-06

Similar Documents

Publication Publication Date Title
AU2020273281B2 (en) Therapeutic uses of ibogaine and related compounds
US20020037925A1 (en) Treatment of addiction and addiction-related behavior
ES2283049T3 (es) (d)-metadona, un analgesico no opiaceo.
US11786490B2 (en) Combination treatments for opioid crisis
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
US6890951B2 (en) Treatment of addiction and addiction-related behavior
AU2002342533B2 (en) Prevention of addiction in pain management
AU2002342533A1 (en) Prevention of addiction in pain management
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
Schumacher et al. Basic and clinical pharmacology
Chen et al. Clonidine attenuates morphine withdrawal and subsequent drug sensitization in rhesus monkeys
NZ518992A (en) Treatment of substance addiction with a mu-opioid receptor antagonist and a calcium channel blocker
CN104666305B (zh) 一种高选择性5‑羟色胺5‑ht2c受体激动剂way163909的用途
CN120661486A (zh) 4-氯-2,5-二甲氧基-n-[（2-甲氧基苯基）甲基]苯乙胺在制备抑制药物成瘾的药物中的应用
KOSTEN et al. Neurobiology of Substance Use Disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired